Published in Adv Funct Mater on June 25, 2013
Tunable delivery of siRNA from a biodegradable scaffold to promote angiogenesis in vivo. Adv Mater (2013) 1.01
A porous tissue engineering scaffold selectively degraded by cell-generated reactive oxygen species. Biomaterials (2014) 0.88
Dual MMP7-proximity-activated and folate receptor-targeted nanoparticles for siRNA delivery. Biomacromolecules (2014) 0.87
Technologies for controlled, local delivery of siRNA. J Control Release (2015) 0.80
Recent Advances in Targeted, Self-Assembling Nanoparticles to Address Vascular Damage Due to Atherosclerosis. Adv Healthc Mater (2015) 0.78
Matrix-metalloproteinases as targets for controlled delivery in cancer: An analysis of upregulation and expression. J Control Release (2017) 0.77
Hydrolytic charge-reversal of PEGylated polyplexes enhances intracellular un-packaging and activity of siRNA. J Biomed Mater Res A (2016) 0.76
Post-nano strategies for drug delivery: Multistage porous silicon microvectors. J Mater Chem B Mater Biol Med (2016) 0.75
The principles and applications of avidin-based nanoparticles in drug delivery and diagnosis. J Control Release (2016) 0.75
Future nanomedicine for the diagnosis and treatment of osteoarthritis. Nanomedicine (Lond) (2014) 0.75
Nanotechnology for cancer treatment. Nanotechnol Rev (2015) 0.75
Particle-based technologies for osteoarthritis detection and therapy. Drug Deliv Transl Res (2016) 0.75
Enzyme-responsive multistage vector for drug delivery to tumor tissue. Pharmacol Res (2016) 0.75
Endothelial glycocalyx conditions influence nanoparticle uptake for passive targeting. Int J Nanomedicine (2016) 0.75
siRNA Delivery Strategies: A Comprehensive Review of Recent Developments. Nanomaterials (Basel) (2017) 0.75
Strategies for using nanoprobes to perceive and treat cancer activity: a review. J Biol Eng (2017) 0.75
Diabetic Retinopathy: Battling the Global Epidemic. Invest Ophthalmol Vis Sci (2016) 0.75
A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res (1986) 15.83
Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles. Nature (2010) 10.09
Impact of tumor-specific targeting on the biodistribution and efficacy of siRNA nanoparticles measured by multimodality in vivo imaging. Proc Natl Acad Sci U S A (2007) 5.17
Metalloproteinases: role in breast carcinogenesis, invasion and metastasis. Breast Cancer Res (2000) 3.41
Discovery and development of folic-acid-based receptor targeting for imaging and therapy of cancer and inflammatory diseases. Acc Chem Res (2007) 3.03
RNA-based therapeutics: current progress and future prospects. Chem Biol (2012) 3.01
Determination of protease cleavage site motifs using mixture-based oriented peptide libraries. Nat Biotechnol (2001) 2.93
The influence of endosome-disruptive peptides on gene transfer using synthetic virus-like gene transfer systems. J Biol Chem (1994) 2.84
Matrix metalloproteinases: multifunctional contributors to tumor progression. Mol Med Today (2000) 2.44
Development of a novel endosomolytic diblock copolymer for siRNA delivery. J Control Release (2008) 2.32
Matrix metalloproteinase-7 is expressed by pancreatic cancer precursors and regulates acinar-to-ductal metaplasia in exocrine pancreas. J Clin Invest (2002) 2.28
Matrilysin: an epithelial matrix metalloproteinase with potentially novel functions. Int J Biochem Cell Biol (1996) 2.12
Polymeric micelle for tumor pH and folate-mediated targeting. J Control Release (2003) 1.93
Sheddable ternary nanoparticles for tumor acidity-targeted siRNA delivery. ACS Nano (2011) 1.74
Sustained local delivery of siRNA from an injectable scaffold. Biomaterials (2011) 1.69
Development of a novel fluorogenic proteolytic beacon for in vivo detection and imaging of tumour-associated matrix metalloproteinase-7 activity. Biochem J (2004) 1.65
pH-responsive polymeric micelle carriers for siRNA drugs. Biomacromolecules (2010) 1.52
Development of a novel systemic gene delivery system for cancer therapy with a tumor-specific cleavable PEG-lipid. Gene Ther (2006) 1.51
Matrix metalloproteinase-2 (MMP-2) is associated with survival in breast carcinoma. Br J Cancer (2003) 1.45
Intracellular delivery of a proapoptotic peptide via conjugation to a RAFT synthesized endosomolytic polymer. Mol Pharm (2010) 1.38
Extracellularly activated nanocarriers: a new paradigm of tumor targeted drug delivery. Mol Pharm (2009) 1.38
Co-delivery of siRNA and paclitaxel into cancer cells by biodegradable cationic micelles based on PDMAEMA-PCL-PDMAEMA triblock copolymers. Biomaterials (2009) 1.34
pH-Responsive nanoparticles for drug delivery. Mol Pharm (2010) 1.33
Protease-triggered unveiling of bioactive nanoparticles. Small (2008) 1.30
Matrilysin (MMP-7) promotes invasion of ovarian cancer cells by activation of progelatinase. Int J Cancer (2005) 1.29
Molecular imaging of proteolytic activity in cancer. J Cell Biochem (2003) 1.19
Action and reaction: the biological response to siRNA and its delivery vehicles. Mol Ther (2012) 1.18
Common MMP-7 polymorphisms and breast cancer susceptibility: a multistage study of association and functionality. Cancer Res (2008) 1.13
pH-responsive sulfonamide/PEI system for tumor specific gene delivery: an in vitro study. Biomacromolecules (2006) 1.13
Nanoparticle self-assembly gated by logical proteolytic triggers. J Am Chem Soc (2007) 1.11
Steric stabilization of poly(2-(dimethylamino)ethyl methacrylate)-based polyplexes mediates prolonged circulation and tumor targeting in mice. J Gene Med (2004) 1.10
Systemic delivery of siRNA to tumors using a lipid nanoparticle containing a tumor-specific cleavable PEG-lipid. Biomaterials (2011) 1.09
Ex vivo red blood cell hemolysis assay for the evaluation of pH-responsive endosomolytic agents for cytosolic delivery of biomacromolecular drugs. J Vis Exp (2013) 1.08
Proteolytic surface functionalization enhances in vitro magnetic nanoparticle mobility through extracellular matrix. Nano Lett (2006) 1.04
Nanoparticle size and surface charge determine effects of PAMAM dendrimers on human platelets in vitro. Mol Pharm (2011) 1.01
Intracellular delivery of a protein antigen with an endosomal-releasing polymer enhances CD8 T-cell production and prophylactic vaccine efficacy. Bioconjug Chem (2010) 1.00
Expression of MMPs and TIMPs genes in human breast cancer epithelial cells depends on cell culture conditions and is associated with their invasive potential. Anticancer Res (2005) 1.00
Genetic polymorphisms in the MMP-7 gene and breast cancer survival. Int J Cancer (2009) 0.98
Design and synthesis of pH-responsive polymeric carriers that target uptake and enhance the intracellular delivery of oligonucleotides. J Control Release (2003) 0.97
Predictive value of MMP-7 expression for response to chemotherapy and survival in patients with non-small cell lung cancer. Cancer Sci (2008) 0.96
Size- and charge-dependent non-specific uptake of PEGylated nanoparticles by macrophages. Int J Nanomedicine (2012) 0.95
MMP-7 overexpression is an independent prognostic marker in gastric cancer. Tumour Biol (2010) 0.95
Preoperative serum MMP-9 immunoreactive protein is a prognostic indicator for relapse-free survival in breast carcinoma. Cancer Lett (2005) 0.94
Physicochemical and biological evaluation of siRNA polyplexes based on PEGylated Poly(amido amine)s. Pharm Res (2011) 0.92
RAFT-synthesized graft copolymers that enhance pH-dependent membrane destabilization and protein circulation times. J Control Release (2011) 0.88
Comparative study of the expression of metalloproteases and their inhibitors in different localizations within primary tumours and in metastatic lymph nodes of breast cancer. Int J Exp Pathol (2010) 0.87
MMP-7 as a prognostic marker in colorectal cancer. Tumour Biol (2010) 0.86
Multifunctional superparamagnetic nanocarriers with folate-mediated and pH-responsive targeting properties for anticancer drug delivery. Biomaterials (2010) 0.86
Thermoresponsive block copolymer-protein conjugates prepared by grafting-from via RAFT polymerization. Macromol Rapid Commun (2011) 0.85
Matrix metalloproteinase-7 (MMP-7) polymorphism is a risk factor for endometrial cancer susceptibility. Clin Chem Lab Med (2010) 0.84
Opsonization, biodistribution, cellular uptake and apoptosis study of PEGylated PBCA nanoparticle as potential drug delivery carrier. Pharm Res (2011) 0.84
Folate targeted polymeric 'green' nanotherapy for cancer. Nanotechnology (2010) 0.82
Matrix metalloproteinase (MMP)-7 in salivary gland cancer. Acta Oncol (2010) 0.82
Matrilysin (MMP-7) cleaves C-type lectin domain family 3 member A (CLEC3A) on tumor cell surface and modulates its cell adhesion activity. J Cell Biochem (2009) 0.81
Proximity-activated nanoparticles: in vitro performance of specific structural modification by enzymatic cleavage. Int J Nanomedicine (2008) 0.80
Polyplexes based on cationic polymers with strong nucleic acid binding properties. Eur J Pharm Sci (2011) 0.79